Uli Brödl & Grünenthal

Uli Brödl: Uli Brödl, as Chief Scientific Officer at Grünenthal, expressed excitement about the successful Phase I trial, highlighting the potential of the NOP agonist to introduce a new mechanism of action in pain treatment.

Grünenthal: Grünenthal successfully completed a Phase I trial for its NOP agonist, demonstrating its safety and tolerability. This positive development allows the company to advance the compound to Phase II trials, potentially leading to a new pain treatment option and enhancing Grünenthal's market position in pain management.

Uli Brödl: As Grünenthal's Chief Scientific Officer, Brödl announced the partnership and expressed support for the collaboration.

Grünenthal: Grünenthal is the main actor, joining CNATM to enhance its oligonucleotide capabilities for pain and neurological diseases. This strengthens its R&D pipeline in genetic medicine.

Uli Brödl: Uli Brödl, Grünenthal's Chief Scientific Officer, commented on the milestone, emphasizing the goal of addressing unmet needs in DMD treatment.

Grünenthal: Grünenthal received FDA designations for its investigational drug tegacorat, a positive regulatory milestone that may enhance its pipeline value and future revenue prospects.